Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 28;25(3):574.
doi: 10.3390/molecules25030574.

Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2-Hydroxyphenylbenzimidazole-based Scaffolds en Route to Donepezil-Like Compounds

Affiliations

Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2-Hydroxyphenylbenzimidazole-based Scaffolds en Route to Donepezil-Like Compounds

Luca Piemontese et al. Molecules. .

Abstract

An unsubstituted 2-hydroxyphenylbenzimidazole has recently been included as a scaffold in a series of hybrids (including the hit compound PZ1) based on the framework of the acetylcholinesterase (AChE) inhibitor Donepezil, which is a new promising multi-target ligand in Alzheimer's disease (AD) treatment. Building upon these findings, we have now designed and completed the whole synthesis of PZ1 in the so-called deep eutectic solvents (DESs), which have emerged as an unconventional class of bio-renewable reaction media in green synthesis. Under optimized reaction conditions, the preparation of a series of 2-hydroxyphenylbenzimidazole-based nuclei has also been perfected in DESs, and comparison with other routes which employ toxic and volatile organic solvents (VOCs) provided. The functionalization of the aromatic ring can have implications on some important biological properties of the described derivatives and will be the subject of future studies of structure-activity relationships (SARs).

Keywords: 2-hydroxyphenylbenzimidazole; Alzheimer’s disease; deep eutectic solvents.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Classical (red, [19]) and new green (blue) procedure for the synthesis of PZ1.
Figure 2
Figure 2
Scope of the cyclodehydration reaction for the synthesis of 2-hydroxyphenylbenzimidazole derivatives 7. Yields refer to isolated products.

References

    1. Cacabelos R. Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years? Expert Opin. Drug Discov. 2018;13:523–538. doi: 10.1080/17460441.2018.1457645. - DOI - PubMed
    1. Piemontese L., Loiodice F., Chaves S., Santos M.A. The Therapy of Alzheimer’s Disease: Towards a New Generation of Drugs. Front. Clin. Drug Res. Alzheimer Disord. 2019;8:33–80.
    1. Fiest K.M., Roberts J.I., Maxwell C.J., Hogan D.B., Smith E.E., Frolkis A., Cohen A., Kirk A., Pearson D., Pringsheim T., et al. The prevalence and incidence of dementia due to Alzheimer’s disease: A systematic review and meta-analysis. Can. J. Neurol. Sci. 2016;43:S51–S82. doi: 10.1017/cjn.2016.36. - DOI - PubMed
    1. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16:877–897. doi: 10.1016/S1474-4422(17)30299-5. - DOI - PMC - PubMed
    1. Cummings J., Aisen P.S., DuBois B., Frölich L., Jack C.R., Jones R.W., Morris J.C., Raskin J., Dowsett S.A., Scheltens P. Drug development in Alzheimer’s disease: The path to 2025. Alzheimers Res. Ther. 2016;8:39. doi: 10.1186/s13195-016-0207-9. - DOI - PMC - PubMed

MeSH terms